Cardioprotection against ischemia/reperfusion injury and chromogranin aderived peptides

Current Medicinal Chemistry

Volumn 19, Issue 24, 2012, Pages 4074-4085

  Penna, C ^a   Tullio, F ^a   Perrelli, M G ^a   Mancardi, D ^a   Pagliaro, P ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cardioprotection; Cardiovascular; Catestatin; Chromogranin A; Ischemia reperfusion; Kinases; Mitochondria; Postconditioning; Preconditioning; Reperfusion injury; Vasostatin

Indexed keywords

CATECHOLAMINE; CATESTATIN; CHROMOGRANIN A; CHROMOGRANIN A1; CYCLIC GMP; NITRIC OXIDE; PEPTIDE DERIVATIVE; PROTEIN KINASE C; UNCLASSIFIED DRUG; VASOSTATIN 1; VASOSTATIN 2;

AMINO ACID SEQUENCE; ARTICLE; CATECHOLAMINE RELEASE; COMORBIDITY; DRUG EFFECT; FEEDBACK SYSTEM; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INOTROPISM; ISCHEMIC PRECONDITIONING; NONHUMAN; REPERFUSION INJURY;

CALRETICULIN; CARDIOTONIC AGENTS; CHROMOGRANIN A; HEART; HUMANS; ISCHEMIC PRECONDITIONING; MITOCHONDRIA; PEPTIDE FRAGMENTS; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY;

EID: 84866696805     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802429966     Document Type: Article

References (168)

1. Garcia-Dorado, D.; Agulló, L.; Sartorio, C.L.; Ruiz-Meana, M. Myocardial protection against reperfusion injury: the cGMP pathway. Thromb. Haemost., 2009, 101(4), 635-642.
2. Aardal, S.; Helle, K.B. The vasoinhibitory activity of bovine Chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul. Pept., 1992, 41(1), 9-18.
3. Angeletti, R.H.; Aardal, S.; Serck-Hanssen, G.; Gee, P.; Helle, K.B. Vasoinhibitory activity of synthetic peptides from the amino terminus of Chromogranin A. Acta Physiol. Scand., 1994, 152(1), 11-19.
4. Helle, K.B.; Metz-Boutigue, M.H.; Aunis, D. Chromogranin A as a calcium binding precursor for multiple regulatory peptides for the immune, endocrine and metabolic systems. Curr. Med. Chem., 2001, 1(2), 119-140.
5. Helle, K.B. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol. Rev. Camb. Philos. Soc., 2004, 79(4), 769-794.
6. Pieroni, M.; Corti, A.; Tota, B.; Curnis, F.; Angelone, T.; Colombo, B.; Cerra, M.C.; Bellocci, F.; Crea, F.; Maseri, A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur. Heart J., 2007, 28(9), 1117-1127.
7. Helle, K.B.; Angeletti, R.H. Chromogranins as multifunctional prohormones: a role in protection against excessive responses to stress? In: The Adrenal Chromaffin Cell: Archetype and Exemplar of Cellular Signalling in Secretory Control; Kanno T, Nakazaku Y, and Kumakura K. Sapporo, ed.; Japan: Hokkaido University Press, 1998
8. Steiner, H.J.; Weiler, R.; Ludescher, C.; Schmid, K.W.; Winkler, H. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J. Histochem. Cytochem., 1990, 38(6), 845-850.
9. Mazza, R.; Gattuso, A.; Mannarino, C.; Brar, B.K.; Barbieri, S.F.; Tota, B.; Mahata, S.K. Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(1), H113-H122.
10. Tota, B.; Gentile, S.; Pasqua,T.; Bassino, E.; Koshimizu, H.; Cawley, N.X.; Cerra, M.C.; Loh, YP; Angelone. T. The novel Chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac betaadrenergic-like inotropes FASEB J. 2012; In press.
11. Tatemoto, K.; Efendic, S.; Mutt, V.; Makk, G.; Feistner, G.J.; Barchas, J.D. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature, 1986, 324(6096), 476-478.
12. Aardal, S.; Helle, K.B.; Elsayed, S.; Reed, R.K.; Serck-Hanssen, G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J. Neuroendocrinol., 1993, 5(4), 405-412.
13. Mahata, S.K.; Mahapatra, N.R.; Mahata, M.; Wang, T.C.; Kennedy, B.P.; Ziegler, M.G.; O'Connor, D.T. Catecholamine secretory vesicle stimulustranscription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J. Biol. Chem., 2003, 278(34), 32058-32067.
14. Mahata, S.K.; Mahata, M.; Parmer, R.J.; O'Connor, D.T. Desensitization of catecholamine release: the novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J. Biol. Chem., 1999, 274(5), 2920-2928.
15. Mahata, S.K.; Mahata, M.; Wakade, A.R.; O'Connor, D.T. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): Identification of amino acid residues crucial for activity. Mol. Endocrinol., 2000, 14(10), 1525-1535.
16. Mahata, S.K.; Mahatam, M.; Wen, G.; Wong, W.B.; Mahapatra, N.R.; Hamilton, B.A.; O'Connor, D.T. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol. Pharmacol., 2004, 66(5), 1180-1191.
17. Mahata, S.K.; O'Connor, D.T.; Mahata, M.; Yoo, S.H.; Taupenot, L.; Wu, H.; Gill, B.M.; Parmer, R.J. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J. Clin. Invest., 1997, 100(6), 1623-1633.
18. Mahata, S.K. Catestatin: the catecholamine release inhibitory peptide: a structural and functional overview. Curr. Med. Chem. Immun. Endoc. Metab. Agents, 2004, 4(3), 221-234.
19. Glattard, E.; Angelone, T.; Strub, J.M.; Corti, A.; Aunis, D.; Tota, B.; Metz-Boutigue, M.H.; Goumon, Y. Characterization of natural vasostatincontaining peptides in rat heart. FEBS. J., 2006, 273(14), 3311-3321.
20. Biswas, N.; Curello, E.; O'Connor, D.T.; Mahata, S.K. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell. Tissue Res., 2010, 342(3), 353-361.
21. Roatta, S.; Passatore, M.; Novello, M.; Colombo, B.; Dondossola, E.; Mohammed, M.; Losano, G.; Corti, A.; Helle, K.B. The chromogranin Aderived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit. Regul. Pept., 2011, 168(1-3), 10-20.
22. Vaingankar, S.M.; Li, Y.; Biswas, N.; Gayen, J.; Choksi, S.; Rao, F.; Ziegler, M.G.; Mahata, S.K.; O'Connor, D.T. Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J. Hypertens., 2010, 28(4), 817-825.
23. Meng, L.; Ye, X.J.; Ding, W.H.; Yang, Y.; Di, B.B.; Liu, L.; Huo, Y. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J. Cardiovasc. Med. (Hagerstown), 2011, 12(9), 643-647.
24. Cappello, S.; Angelone, T.; Tota, B.; Pagliaro, P.; Penna, C.; Rastaldo, R.; Corti, A.; Losano, G.; Cerra, M.C. Human recombinant chromogranin Aderived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am. J. Physiol. Heart Circ. Physiol., 2007, 293(1), H719-H727.
25. Penna, C.; Alloatti, G.; Gallo, M.P.; Cerra, M.C.; Levi, R.; Tullio, F.; Bassino, E.; Dolgetta, S.; Mahata, S.K.; Tota, B.; Pagliaro, P. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell. Mol. Neurobiol., 2010, 30(8), 1171-1179.
26. Helle, K.B.; Serck-Hanssen, G.; Aardal, S. Functional aspects of the adrenal medullary chromogranins. Neurochem. Int., 1993, 22(4), 353-360.
27. Metz-Boutigue, M.H.; Kieffer, A.E.; Goumon, Y.; Aunis, D. Innate immunity: involvement of new neuropeptides. Trends Microbiol., 2003, 11(12), 585-592.
28. Ratti, S.; Curnis, F.; Longhi, R.; Colombo, B.; Gasparri, A.; Magni, F.; Manera, E.; Metz-Boutigue, M.H.; Corti, A. Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J. Biol. Chem., 2000, 275(38), 29257-29263.
29. Angeletti, R.H.; Mints, L.; Aber, C.; Russell, J. Determination of residues in chromogranin A-(16-40) required for inhibition of parathyroid hormone secretion. Endocrinology, 1996, 137(7), 2918-2922.
30. Angeletti, R.H.; D'Amico, T.; Russell, J. Regulation of parathyroid secretion. Chromogranins, chemokines, and calcium. Adv. Exp. Med. Biol., 2000, 482, 217-223.
31. Tota, B.; Mazza, R.; Angelone, T.; Nullans, G.; Metz-Boutigue, M.H.; Aunis, D.; Helle, K.B. Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart. Regul. Pept., 2003, 114(2-3), 123-130.
32. Helle, K.B.; Aunis, D. A physiological role for the granins as prohormones for homeostatically important regulatory peptides? A working hypothesis for future research. Adv. Exp. Med. Biol., 2000, 482, 389-397.
33. Imbrogno, S.; Angelone, T.; Corti, A.; Adamo, C.; Helle, K.B.; Tota, B. Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen. Comp. Endocrinol., 2004, 139(1), 20-28.
34. Corti, A.; Mannarino, C.; Mazza, R.; Angelone, T.; Longhi, R.; Tota, B. Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiostatins on the isolated working frog heart. Gen. Comp. Endocrinol., 2004, 136(2), 217-224.
35. O'Connor, D.T.; Kailasam, M.T.; Kennedy, B.P.; Ziegler, M.G.; Yanaihara, N.; Parmer, R.J. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J. Hypertens., 2002, 20(7), 1335-1345.
36. Angelone, T.; Quintieri, A.M.; Brar, B.K.; Limchaiyawat, P.T.; Tota, B.; Mahata, S.K.; Cerra, M.C. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology., 2008, 149(10), 4780-4793.
37. Cerra, M.C.; De Iuri, L.; Angelone, T.; Corti, A.; Tota, B. Recombinant Nterminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res. Cardiol., 2006, 101(1), 43-52.
38. Tota, B.; Imbrogno, S.; Mannarino, C.; Mazza, R. Vasostatins and negative inotropy in vertebrate hearts. Curr. Med. Chem., 2004, 4(3), 195-201.
39. Cerra, M.C.; Gallo, M.P.; Angelone, T.; Quintieri, A.M.; Pulerà, E.; Filice, E.; Guérold, B.; Shooshtarizadeh, P.; Levi, R.; Ramella, R.; Brero, A.; Boero, O.; Metz-Boutigue, M.H.; Tota, B.; Alloatti, G. The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB J., 2008, 22(11), 3992-4004.
40. Ramella, R.; Boero, O.; Alloatti, G.; Angelone, T.; Levi, R.; Gallo, M.P. Vasostatin 1 activates eNOS in endothelial cells through a proteoglycandependent mechanism. J. Cell. Biochem., 2010, 110(1), 70-79.
41. Angelone, T.; Quintieri, A.M.; Goumon, Y.; Di Felice, V.; Filice, E.; Gattuso, A.; Mazza, R.; Corti, A.; Tota, B.; Metz-Boutigue, M.-H.; Cerra, M.C. Cytoskeleton mediates negative inotropism and lusitropism of Chromogranin A-derived peptides (human vasostatin1-78 and rat CgA1-64) in the rat heart. Regul. Pep., 2010, 165(1), 78-85.
42. Gallo, M.P.; Levi, R.; Ramella, R.; Brero, A.; Boero, O.; Tota, B.; Alloatti, G. Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium. Am. J. Physiol. Heart. Circ. Physiol., 2007, 292(6), H2906-H2912.
43. Abi-Gerges, N.; Fischmeister, R.; Mery, P.F. G protein-mediated inhibitory effect of a nitric oxide donor on the L-type Ca2+ current in rat ventricular myocytes. J. Physiol., 2001, 531(Pt 1), 117-1130.
44. Hove-Madsen, L.; Mery, P.F.; Jurevicius, J.; Skeberdis, A.V.; Fischmeister, R. Regulation of myocardial calcium channels by cyclic AMP metabolism. Basic Res. Cardiol., 1996, 91 Suppl 2, 1-8.
45. Mery, P.F.; Lohmann, S.M.; Walter, U.; Fischmeister, R. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc. Natl. Acad. Sci. USA, 1991, 88(4), 1197-1201.
46. Miyamoto, A.; Laufs, U.; Pardo, C.; Liao, J.K. Modulation of bradykinin receptor ligand binding affinity and its coupled G-proteins by nitric oxide. J. Biol. Chem., 1997, 272(31), 19601-19608.
47. Pfeiffer, C.J.; Qiu, B.S. Effects of chronic nitric oxide synthase inhibition on TNB-induced colitis in rats. J. Pharm. Pharmacol., 1995, 47(10), 827-832.
48. Bassino, E.; Fornero, S.; Gallo, M.P.; Ramella, R.; Mahata, S.K.; Tota, B.; Levi, R.; Alloatti, G. A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K-eNOS pathway in the myocardium. Cardiovasc. Res., 2011, 91(4), 617-624.
49. Jordan, J.E.; Zhao, Z.Q.; Vinten-Johansen, J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc. Res., 1999, 43(4), 860-878.
50. Piper, H.M.; Meuter, K.; Schäfer, C. Cellular mechanisms of ischemiareperfusion injury. Ann. Thorac. Surg., 2003, 75(2), S644-S648.
51. Pagliaro, P.; Moro, F.; Tullio, F.; Perrelli, M.G.; Penna, C. Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid. Redox Signal., 2011, 14(5), 833-850.
52. Zhao, Z.Q.; Vinten-Johansen, J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc. Res., 2002, 55(3), 438-455.
53. Gottlieb, R.A.; Mentzer, R.M. Autophagy during cardiac stress: joys and frustrations of autophagy. Ann. Rev. Physiol., 2010, 72, 45-59.
54. Tritto, I.; Ambrosio, G. Role of oxidants in the signaling pathway of preconditioning. Antioxid. Redox Signal., 2001, 3(1), 3-10.
55. Ambrosio, G.; Flaherty, J.T.; Duilio, C.; Tritto, I.; Santoro, G.; Elia, P.P.; Condorelli, M.; Chiariello, M. Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J. Clin. Invest., 1991, 87(6), 2056-2066.
56. Ambrosio, G.; Zweier, J.L.; Duilio, C.; Kuppusamy, P.; Santoro, G.; Elia, P.P.; Tritto, I.; Cirillo, P.; Condorelli, M.; Chiariello, M.; Flaherty, J.T. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J. Biol. Chem., 1993, 268(25), 18532-18541.
57. Hoffman, J.W. Jr, Gilbert, T.B.; Poston, R.S.; Silldorff, E.P. Myocardial reperfusion injury: etiology, mechanisms, and therapies. J. Extra Corpor. Technol., 2004, 36(4), 391-411.
58. Zhao, Z.Q. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr. Opin. Pharmacol., 2004, 4(2), 159-165.
59. Kaeffer, N.; Richard, V.; Thuillez, C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation, 1997, 96(7), 2311-2316.
60. Beauchamp, P.; Richard, V.; Tamion, F.; Lallemand, F.; Lebreton, J.P.; Vaudry, H.; Daveau, M.; Thuillez, C. Protective effects of preconditioning in cultured rat endothelial cells: effects on neutrophil adhesion and expression of ICAM-1 after anoxia and reoxygenation. Circulation, 1999, 100(5), 541-546.
61. Lefer, A.M.; Lefer, D.J. Endothelial dysfunction in myocardial ischemia and reperfusion: role of oxygen-derived free radicals. Basic Res. Cardiol., 1991, 86 Suppl 2, 109-116.
62. Ronson, R.S.; Nakamura, M.; Vinten-Johansen, J. The cardiovascular effects and implications of peroxynitrite. Cardiovasc. Res., 1999, 44(1), 47-59.
63. Ferdinandy, P.; Schulz, R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol., 2003, 138(4), 532-543.
64. Penna, C.; Perrelli, M.G.; Tullio, F.; Moro, F.; Parisella, M.L.; Merlino, A.; Pagliaro, P. Post-ischemic early acidosis in cardiac postconditioning modifies the activity of antioxidant enzymes, reduces nitration, and favors protein S-nitrosylation. Pflugers. Arch., 2011, 462(2), 219-2133.
65. Siegmund, B.; Schluter, K.D.; Piper, H.M. Calcium and the oxygen paradox. Cardiovasc. Res., 1993, 27(10), 1778-1783.
66. Gateau-Roesch, O.; Argaud, L.; Ovize, M. Mitochondrial permeability transition pore and postconditioning. Cardiovasc. Res., 2006, 70(2), 264-273.
67. Halestrap, A.P. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem. Soc. Trans., 2006, 34(Pt 2), 232-237.
68. Halestrap, A.P. Mitochondria and reperfusion injury of the heart-a holey death but not beyond salvation. J. Bioenerg. Biomembr., 2009, 41(2), 113-121.
69. Juhaszova, M.; Zorov, D.B.; Yaniv, Y. ; Nuss, H.B.; Wang, S.; Sollott, S.J. Role of glycogen synthase kinase-3beta in cardioprotection. Circ. Res., 2009, 104(11), 1240-1252.
70. Zorov, D.B.; Juhaszova, M.; Yaniv, Y.; Nuss, H.B.; Wang, S.; Sollott, S.J. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc. Res., 2009, 83(2), 213-225.
71. Schreck, R.; Albermann, K.; Baeuerle, P.A. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic. Res. Commun., 1992, 17(4), 221-237.
72. Lefer, A.M.; Lefer, D.J. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc. Res., 1996, 32(4), 743-751.
73. Baldwin, A.L.; Thurston, G. Mechanics of endothelial cell architecture and vascular permeability. Crit. Rev. Biomed. Eng., 2001, 29(2), 247-278.
74. Marczin, N.; El-Habashi, N.; Hoare, G.S.; Bundy, R.E.; Yacoub, M. Antioxidants in myocardial ischemia-reperfusion injury: Therapeutic potential and basic mechanisms. Arch. Biochem. Biophys., 2003, 420(2), 222-236.
75. Radomski, M.W.; Palmer, R.M.; Moncada, S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun., 1987, 148(3), 1482-1489.
76. Schulz, R.; Kelm, M.; Heusch, G. Nitric oxide in myocardial ischemia reperfusion injury. Cardiovasc. Res., 2004, 61(3), 402-413.
77. Reffelmann, T.; Kloner, RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart., 2002, 87(2), 162-168.
78. Maroko, P.R.; Kjekshus, J.K.; Sobel, B.E.; Watanabe, T.; Covell, J.W.; Ross, J.; Jr.; Braunwald, E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation, 1971, 43(1), 67-82.
79. Maroko, P.R.; Libby, P.; Ginks, W.R.; Bloor, C.M.; Shell, W.E.; Sobel, B.E.; Ross, J.; Jr. Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J. Clin. Invest., 1972, 51(10), 2710-2716.
80. Murry, C.E.; Jennings, R.B.; Reimer, K.A. New insights into potential mechanisms of ischemic preconditioning. Circulation., 1991, 84(1), 442-445.
81. Liu, G.S.; Thornton, J.; Van Winkle, D.M.; Stanley, A.W.H.; Olsson, R.A.; Downey, J.M. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation, 1991, 84(1), 350-356.
82. Bolli, R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J. Mol. Cell. Cardiol., 2001, 33(11), 1897-1918.
83. Dawn, B.; Bolli, R. Role of nitric oxide in myocardial preconditioning. Ann. N. Y. Acad. Sci., 2002, 962, 18-41.
84. Hausenloy, D.J.; Yellon, D.M. Preconditioning and postconditioning: new strategies for cardioprotection. Diabetes Obes. Metab., 2008, 10(6), 451-459.
85. Hausenloy, D.J.; Yellon, D.M. Preconditioning and postconditioning: united at reperfusion. Pharmacol. Ther., 2007, 116(2), 173-191.
86. Yellon, D.M.; Downey, J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev., 2003, 83(4), 1113-1151.
87. Yellon, D.M.; Hausenloy, D.J. Myocardial reperfusion injury. N. Engl. J. Med., 2007, 357(11), 1121-1135.
88. Wink, D.A.; Miranda, K.M.; Katori, T.; Mancardi, D.; Thomas, D.D.; Ridnour, L.; Espey, M.G.; Feelisch, M.; Colton, C.A.; Fukuto, J.M.; Pagliaro, P.; Kass, D.A.; Paolocci, N. Orthogonal properties of the redox siblings nitroxyl and nitric oxide in the cardiovascular system: a novel redox paradigm. Am. J. Physiol. Heart Circ. Physiol., 2003, 285(6), H2264-H2276.
89. Pagliaro, P. Differential biological effects of products of nitric oxide (NO) synthase: it is not enough to say NO. Life Sci., 2003, 73(17), 2137-2149.
90. Penna, C.; Mancardi, D.; Raimondo, S.; Geuna, S.; Pagliaro, P. The paradigm of postconditioning to protect the heart. J. Cell. Mol. Med., 2008, 12(2), 435-458.
91. Gomez, L.; Thibault H.B.; Gharib, A.; Dumont, J.M.; Vuagniaux, G.; Scalfaro, P.; Derumeaux, G.; Ovize, M. Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am. J. Physiol, Heart Circ. Physiol., 2007, 293(3), H1654-H1661.
92. Hausenloy, D.J.; Yellon, D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail. Rev., 2007, 12(3-4), 217-234.
93. Juhaszova, M.; Zorov, D.B.; Kim, S.H.; Pepe, S.; Fu, Q.; Fishbein, K.W.; Ziman, B.D.; Wang, S.; Ytrehus, K.; Antos, C.L.; Olson, E.N.; Sollott, S.J.; Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest., 2004, 113(11), 1535-1549.
94. Lim, S.Y.; Davidson, S.M.; Hausenloy, D.J.; Yellon, D.M. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc. Res., 2007, 75(3), 530-535.
95. Weiss, J.N.; Korge, P.; Honda, H.M.; Ping, P. Role of the mitochondrial permeability transition in myocardial disease. Circ. Res., 2003, 93(4), 292-301.
96. Carroll, R.; Gant, V.A.; Yellon, D.M. Mitochondrial KATP channels protects a human atrial-derived cell line by a mechanism involving free radical generation. Cardiovasc. Res., 2001, 51(4), 691-700.
97. Cohen, M.V.; Yang, X.M.; Liu, G.S.; Heusch, G.; Downey, J.M. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial KATP channels. Circ. Res., 2001, 89(3), 273-278.
98. Forbes, R.A.; Steenbergen, C.; Murphy, E. Diazoxide induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ. Res., 2001, 88(8), 802-809.
99. Garlid, K.D.; Dos Santos, P.; Xie, Z.J.; Costa, A.D.; Paucek, P. Mitochondrial potassium transport: the role of the mitochondrial ATPsensitive K(+) channel in cardiac function and cardioprotection. Biochim. Biophys. Acta, 2003, 1606(1-3), 1-21.
100. O'Rourke, B. Myocardial K(ATP) channels in preconditioning. Circ. Res., 2000, 87(10), 845-855.
101. Oldenburg, O.; Cohen, M.V.; Yellon, D.M.; Downey, J.M. Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc. Res., 2002, 55(3), 429-437.
102. Oldenburg, O.; Qin, Q.; Krieg, T.; Yang, X.M.; Philipp, S.; Critz, S.D.; Cohen, M.V.; Downey, J.M. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am. J. Physiol, Heart Circ. Physiol., 2004, 286(1), H468-H476.
103. Yue, Y.; Qin, Q.; Cohen, M.V.; Downey, J.M.; Critz, S.D. The relative order of mK(ATP) channels, free radicals and p38 MAPK in preconditioning's protective pathway in rat heart. Cardiovasc. Res., 2002, 55(3), 681-689.
104. Tissier, R.; Cohen, M.V.; Downey, J.M. Protecting the acutely ischemic myocardium beyond reperfusion therapies: are we any closer to realizing the dream of infarct size elimination? Arch. Mal. Coeur. Vaiss., 2007, 100(9), 794-802.
105. Philipp, S.; Yang, X.-M.; Cui, L.; Davis, A.M.; Downey, J.M.; Cohen, M.V. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc. Res., 2006, 70(2), 308-314.
106. Kuno, A.; Solenkova, N.V.; Solodushko, V.; Dost, T.; Liu, Y.; Yang, X.-M.; Cohen, M.V.; Downey, J.M. Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C. Am. J. Physiol., 2008, 295(3), H1288-H1295.
107. Perrelli, M.G.; Pagliaro, P.; Penna, C. Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. World J. Cardiol., 2011, 3(6), 186-200.
108. Hausenloy, D.J.; Lecour, S.; Yellon, D.M. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid. Redox Signal., 2011, 14(5), 893-907.
109. Fujio, Y.; Nguyen, T.; Wencker, D.; Kitsis, R.N.; Walsh, K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation., 2000, 101(6), 660-667.
110. Matsui, T.; Li, L.; del Monte, F.; Fukui, Y.; Franke, T.F.; Hajjar, R.J.; Rosenzweig, A. Adenoviral gene transfer of activated phosphatidylinositol 3-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation., 1999, 100(23), 2373-2379.
111. Craig, R.; Wagner, M.; McCardle, T.; Craig, A.G.; Glembotski, C.C. The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kappa B. J. Biol. Chem., 2001, 276(40), 37621-37629.
112. Negoro, S.; Oh, H.; Tone, E.; Kunisada, K.; Fujio, Y.; Walsh, K.; Kishimoto, T.; Yamauchi-Takihara, K. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation., 2001, 103(4), 555-561.
113. Miyamoto, S.; Murphy, A.N.; Brown, J.H. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell. Death Differ., 2008, 15(3), 521-529.
114. Cohen, M.V.; Downey, J.M. Adenosine: trigger and mediator of cardioprotection. Basic Res. Cardiol., 2008, 103(3), 203-215.
115. Means, C.K.; Miyamoto, S.; Chun, J.; Brown, J.H. S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J. Biol. Chem., 2008, 283(18). 11954-11963.
116. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307(5712), 1098-1101.
117. Newton, A.C. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem. J., 2003, 370(Pt 2), 361-371.
118. Goodman, M.D.; Koch, S.E.; Fuller-Bicer, G.A. Butler, K.L. Regulating RISK: a role for JAK-STAT signaling in postconditioning? Am. J. Physiol. Heart Circ. Physiol., 2008, 295(4), H1649-H1656.
119. Gross, E.R.; Hsu, A.K.; Gross, G.J. The JAK/STAT pathway is essential for opioid induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am. J. Physiol. Heart Circ. Physiol., 2006, 291(2), H827-H834.
120. Boengler, K.; Hilfiker-Kleiner, D.; Drexler, H.; Heusch, G.; Schulz, R. The myocardial JAK/STAT pathway:from protection to failure. Pharmacol. Therap., 2008, 120(2), 172-185.
121. Lacerda, L.; Somers, S.; Opie, L.H.; Lecour, S. Ischemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc. Res., 2009, 84(2), 201-208.
122. Wegrzyn, J.; Potla, R.; Chwae, Y.J.; Sepuri, N.B.; Zhang, Q.; Koeck, T.; Derecka, M.; Szczepanek, K.; Szelag, M.; Gornicka, A.; Moh, A.; Moghaddas, S.; Chen, Q.; Bobbili, S.; Cichy, J.; Dulak, J.; Baker, D.P.; Wolfman, A.; Stuehr, D.; Hassan, M.O.; Fu, X.Y.; Avadhani, N.; Drake, J.I.; Fawcett, P.; Lesnefsky, E.J, Larner, A.C. Function of mitochondrial Stat3 in cellular respiration. Science, 2009, 323(5915), 793-797.
123. Boengler, K.; Hilfiker-Kleiner, D.; Heusch, G.; Schulz, R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res. Cardiol., 2010, 105(6), 771-785.
124. Boengler, K.; Heusch G.; Schulz, R. Mitochondria in postconditioning. Antioxid. Redox Signal., 2011, 1813(7), 1286-1294.
125. McCormick, J.; Barry, S.P.; Sivarajah, A.; Stefanutti, G.; Townsend, P.A.; Lawrence, K.M.; Eaton, S.; Knight, R.A.; Thiemermann, C.; Latchman, D.S.; Stephanou, A. Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. FASEB J., 2006, 20(12), 2115-2117.
126. Negoro, S.; Kunisada, K.; Tone, E.; Funamoto, M.; Oh, H.; Kishimoto, T, Yamauchi-Takihara, K. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc. Res., 2000, 47(4), 797-805.
127. Fuglesteg, B.N.; Suleman, N.; Tiron, C.; Kanhema, T.; Lacerda, L.; Andreasen, T.V.; Sack, M.N.; Jonassen, A.K.; Mjøs, O.D.; Opie, L.H.; Lecour, S. Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res. Cardiol., 2008, 103(5), 444-453.
128. Kelly, R.F.; Lamont, K.T.; Somers, S.; Hacking, D.; Lacerda, L.; Thomas, P, Opie, L.H.; Lecour, S. Ethanolamine is a novel STAT-3 dependent cardioprotective agent. Basic Res. Cardiol., 2010, 105(6), 763-770.
129. Lecour, S.; Suleman, N.; Deuchar, G.A.; Somers, S.; Lacerda, L.; Huisamen, B.; Opie L.H. Pharmacological preconditioning with tumor necrosis factoralpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation, 2005, 112(25), 3911-3918.
130. Boengler, K.; Buechert, A.; Heinen, Y.; Roeskes, C.; Hilfiker-Kleiner, D.; Heusch, G.; Schulz, R. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ. Res., 2008, 102(1), 131-135.
131. Lecour, S. Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J. Mol. Cell. Cardiol., 2009, 47(1), 32-40.
132. Obana, M.; Maeda, M.; Takeda, K.; Hayama, A.; Mohri, T.; Yamashita, T.; Nakaoka, Y.; Komuro, I.; Takeda, K.; Matsumiya, G.; Azuma, J.; Fujio, Y. Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation, 2010, 121(5), 684-691.
133. Hattori, R.; Maulik, N.; Otani, H.; Zhu, L.; Cordis, G.; Engelman, R.M.; Siddiqui, MA.; Das, DK. Role of STAT3 in ischemic preconditioning. J. Mol. Cell. Cardiol., 2001, 33(11), 1929-1936.
134. Pagliaro, P.; Mancardi, D.; Rastaldo, R.; Penna, C.; Gattullo, D.; Miranda, K.M.; Feelisch, M.; Wink, D.A.; Kass, D.A.; Paolocci, N. Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic. Biol. Med., 2003, 34(1), 33-43.
135. Cohen, M.V.; Downey, JM. Ischemic postconditioning: from receptor to end-effector. Antioxid. Redox Signal., 2011, 14(5), 821-831.
136. Cohen, M.V.; Baines, C.P.; Downey, J.M. Ischemic preconditioning: from adenosine receptor to KATP channel. Annu. Rev. Physiol., 2000, 62, 79-109.
137. Cohen, M.V.; Yang X.M.; Downey, J.M. Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct sparing strategies. Cardiovasc. Res., 2006, 70(2), 231-239.
138. Peart, J.N.; Gross, G.J. Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am. J. Physiol. Heart. Circ. Physiol., 2003, 285(1), H81-H89.
139. Penna, C.; Alloatti, G.; Cappello, S.; Gattullo, D.; Berta, G.; Mognetti, B.; Losano, G.; Pagliaro, P. Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am. J. Physiol. Heart. Circ. Physiol., 2005, 288(5), H2512-H2520.
140. Wang, X.; Xu, S.; Liang, Y.; Zhu, D.; Mi, L.; Wang, G.; Gao, W. Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction. Biomarkers, 2011, 16(4), 372-277.
141. Zhao, Z.Q.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.; Wang, N.P.; Guyton, R.A.; Vinten-Johansen, J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2003, 285(2), H579-H588.
142. Penna, C.; Cappello, S.; Mancardi, D.; Raimondo, S.; Rastaldo, R.; Gattullo, D.; Losano, G.; Pagliaro, P. Post-conditioning reduces infarct size in the isolated rat heart: Role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res. Cardiol., 2006, 101(2), 168-179.
143. Penna, C.; Rastaldo, R.; Mancardi, D.; Raimondo, S.; Cappello, S.; Gattullo, D.; Losano, G.; Pagliaro, P. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATPsensitive K+ channel and protein kinase C activation. Basic Res. Cardiol., 2006, 101(2), 180-9.
144. Tsang, A.; Hausenloy, D.J.; Mocanu, M.M.; Yellon, D.M. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ. Res., 2004, 95(3), 230-232.
145. Yang, X.M.; Proctor, J.B.; Cui, L.; Krieg, T.; Downey, J.M.; Cohen, M.V. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J. Am. Coll. Cardiol., 2004, 44(5), 1103-1110.
146. Kaur, S.; Jaggi, A.S.; Singh, N. Molecular aspects of ischaemic postconditioning. Fundam. Clin. Pharmacol., 2009, 23(5), 521-536.
147. Ceconi, C.; Ferrari, R.; Bachetti, T.; Opasich, C.; Volterrani, M.; Colombo, B.; Parrinello, G.; Corti, A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur. Heart J., 2002, 23, 967-974.
148. Omland, T.; Dickstein, K.; Syversen, U. Association between plasma chromogranin A concentration and long-term mortality after MI. Am. J. Med., 2003, 114(1), 25-30.
149. Penna, C., Angelone, T., Perrelli, M.G., Tota, B., Alloatti, G., Cerra, M.C., Pagliaro, P. Postconditioning (PostC)-like cardioprotective effects by chromogranin A (CgA)-derived catestatin (CTS) in isolated hearts is mediated by RISK (reperfusion injury salvage kinases) pathway. Acta Physiol., 2011, 203(S688), P3.23
150. Heusch, G. No risk, no cardioprotection? A critical perspective. Cardiovasc. Res., 2009, 84(2), 173-5.
151. Penna, C.; Mancardi, D.; Rastaldo, R.; Losano, G.; Pagliaro, P. Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc. Res., 2007, 75(1), 168-177.
152. Leary, P.J.; Rajasekaran, S.; Morrison, R.R.; Tuomanen, E.I.; Chin, T.K.; Hofmann, P.A. A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(6), H2775-H2784.
153. Penna, C.; Bassino, E.; Alloatti, G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp. Biol. Med. (Maywood)., 2011, 236(4), 390-401.
154. Ma, X.L.; Gao, F.; Liu, G.L.; Lopez, B.L.; Christopher, T.A.; Fukuto, J.M.; Wink, D.A.; Feelisch, M. Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. Proc. Natl. Acad. Sci. USA., 1999, 96(25), 14617-14622.
155. Rastaldo, R.; Cappello, S.; Folino, A.; Berta, G.N.; Sprio, A.E.; Losano, G.; Samaja, M.; Pagliaro, P. Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am. J. Physiol. Heart Circ. Physiol., 2011, 300(6), H2308-H2315.
156. Simpkin, J.C.; Yellon, D.M.; Davidson, S.M.; Lim, S.Y:; Wynne, A.M.; Smith, C.C. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic. Res. Cardiol., 2007, 102(6), 518-528
157. Omland, T.; Dickstein, K.; Syversen, U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am. J. Med., 2003, 114(1), 25-30.
158. Nobels, F. R.; De Herder, W.W.; Kwekkeboom, D.J.; Coopmans, W.; Mulder, A.; Bouillon, R.; and Lamberts, S.W. Serum chromogranin A in the differential diagnosis of Cushing's syndrome. Eur. J. Endocrinol.; 1994, 131(6), 589-593.
159. Hsiao, R. J.; Mezger, M. S.; O'Connor, D. T. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int., 1990, 37(3), 955-964.
160. O'Connor, D. T.; Takiyyuddin, M. A.; Printz, M. P.; Dinh, T. Q.; Barbosa, J. A.; Rozansky, D. J.; Mahata, S. K.; Wu, H.; Kennedy, B. P.; Ziegler, M. G.; Wright, F. A.; Schlager, G.; Parmer, R. J. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press., 1999, 8(5-6), 285-295.
161. Mahapatra, N. R.; O'Connor, D. T.; Vaingankar, S. M.; Hikim, A. P.; Mahata, M.; Ray Staite, E.; Wu, H.; Gu, Y.; Dalton, N.; Kennedy, B. P.; Ziegler, M. G.; Ross, J.; Mahata, S. K. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J. Clin. Invest., 2005, 115(7), 1942-1952.
162. O'Connor, D.T. Plasma chromogranin A. Initial studies in human hypertension. Hypertension, 1985, 7(3 Pt 2), I76-I79.
163. Chen, Y.; Rao, F; Rodriguez-Flores, J.L.; Mahata, M.; Fung, M.M.; Stridsberg, M.; Vaingankar, S.M.; Wen, G.; Salem, R.M.; Das, M.; Cockburn, M.G.; Schork, N.J.; Ziegler, M.G.; Hamilton, B.A.; Mahata, S.K.; Taupenot, L.; O'Connor, D.T. Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J. Am. Coll. Cardiol., 2008, 52(18), 1468-1481.
164. Penna C, Tullio F, Moro F, Folino A, Merlino A, Pagliaro P. Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. Basic. Res. Cardiol., 2010, 105(2), 181-192.
165. Angelone T. , Penna C. , Perrelli M. , Tota B. , Cerra M. C. , Pagliaro P. Postconditioning (PostC)-like cardioprotective effects by chromogranin A (CgA)-derived catestatin (CTS) in isolated hearts of spontaneous hypertensive rat (SHR). Acta Physiol., 2011, 203(S688), P3.1.
166. Koeslag, J.H.; Saunders, P.T.; Wessels, J.A. The chromogranins and the counter-regulatory hormones: do they make homeostatic sense? J. Physiol, 1999, 517(3), 643-649.
167. Zhang, K.; Rao, F.; Wen, G.; Salem, R.M.; Vaingankar, S.; Mahata, M.; Mahapatra, N.R.; Lillie, E.O.; Cadman, P.E.; Friese, R.S.; Hamilton, B.A.; Hook, V.Y.; Mahata, S.K.; Taupenot, L.; O'Connor, D.T. Catecholamine storage vesicles and the metabolic syndrome: The role of thechromogranin A fragment pancreastatin. Diabetes Obes Metab. 2006, 8(6), 621-633.
168. Helle, K.B.; Corti, A.; Metz-Boutigue, M.H.; Tota, B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell. Mol. Life Sci., 2007, 64(22), 2863-2886.